A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Phase 2 Completed 73 enrolled Neurocrine Biosciences

RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

Timeline

Start: 2024-03-20
Primary completion: 2025-07-25
Completion: 2025-09-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NBI-1070770	Unknown	—	Oral

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Summary

Timeline

Drugs

Indications